Skip to main content
NANOVIRICIDES, INC. logo

NANOVIRICIDES, INC. — Investor Relations & Filings

Ticker · NNVC ISIN · US6300873022 LEI · 5493003CK9Y2H0OORR73 US Professional, scientific and technical activities
Open in API
Filings indexed 537 across all filing types
Latest filing 2007-03-20 Annual Report
Country US United States of America
Listing US NNVC

About NANOVIRICIDES, INC.

https://www.nanoviricides.com/

NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing a novel class of nanomedicine-based antiviral therapeutics. The company's proprietary platform technology creates "nanoviricides," which are designed to be broad-spectrum drugs that viruses cannot easily evade through mutation. The technology is biomimetic, mimicking the host cell receptors that viruses use for entry. A nanoviricide is engineered to attract and bind to a virus particle, subsequently trapping and dismantling it to neutralize the threat. The company's development pipeline targets a wide range of viral infections, including respiratory viruses such as RSV, influenza, and coronaviruses, as well as herpesviruses (shingles, cold sores), HIV, and hemorrhagic fever viruses.

Recent filings

Filing Released Lang Actions
NANOVIRICIDES 10-SB12G/A
Annual Report Classification · 95% confidence The document is titled 'FORM 10-SB/A Amendment No. 3' and is a registration statement filed pursuant to the Securities Exchange Act of 1934. It includes detailed sections such as Description of Business, Management Discussion and Analysis, Description of Property, Security Ownership, Directors and Officers, Executive Compensation, Legal Procedures, and Financial Statement Schedules. The document is comprehensive and contains substantive business and financial information about NanoViricides, Inc., including forward-looking statements, corporate history, and technology description. The length is about 15,000 characters, indicating a full report rather than a brief announcement or certification. The form 10-SB is a type of annual report for small business issuers, similar in nature to a 10-K but for smaller companies. Given the detailed business description, financial data, and regulatory context, this filing fits the definition of an Annual Report (10-K equivalent for small businesses). Therefore, the appropriate classification is Annual Report (10-K).
2007-03-20 English
NANOVERCIDES 8K 3/7/2007
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (a sublease agreement) and includes the signature of the CEO. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, voting result, or management change announcement. It is a regulatory filing reporting a material event, which fits the category of Regulatory Filings (RNS). The document length is short (2527 characters), and it is a standalone event report rather than a full report or announcement of a report publication.
2007-03-08 English
Regulatory Filings 2007
Regulatory Filings
2007-02-27 English
NANOVIRICIDES 10-QSB 12-31-2006
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FORM 10-QSB' and is a quarterly report filed under the Securities Exchange Act of 1934 for the period ended December 31, 2006. It contains detailed financial statements including balance sheets, statements of operations, changes in shareholders' equity, and cash flows, as well as management's discussion and analysis, controls and procedures, legal proceedings, and other information. The length of the document is approximately 15,000 characters, indicating it is a full report rather than a brief announcement. The presence of unaudited financial statements and the quarterly period end date confirm this is an interim quarterly report. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2007-02-15 English
Regulatory Filings 2007
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically references a late filing of a quarterly report on Form 10-QSB and explains the reasons for the delay. The document does not contain the actual financial data or the quarterly report itself but is a notification about the delay in filing that report. The document length is 4293 characters, which is relatively short and consistent with a notification form rather than a full report. According to the rules, such a notification form should be classified as a Regulatory Filing (RNS) because it is a compliance document notifying the SEC of a late filing, not the report itself.
2007-02-15 English
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a detailed correspondence letter from the company's legal counsel to the SEC regarding amendments and responses to comments on a Form 10-SB12G filing. It discusses revisions to a registration statement, preclinical study results, statistical analysis explanations, and confidential treatment requests. The document is not the actual Form 10-SB12G filing itself but a letter addressing SEC comments and amendments to that filing. It contains no standalone financial statements or comprehensive financial performance data. It is a regulatory correspondence related to a specific SEC filing, thus best classified as a Regulatory Filing (RNS).
2007-02-14 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.